Lucideon to Support Wockhardt to get the COVID-19 Vaccine to Market
Lucideon has been chosen by Wockhardt, the global pharmaceutical and biotechnology organization, to support with testing of the COVID-19 vaccine.
The international product testing and process consultancy will test part of the Wockhardt-manufactured fill finished vaccines, to verify that they are in specification and therefore fit for use.
Testing will be carried out at Lucideon's global headquarters in Stoke-on-Trent, home to its Good Manufacturing Practice (GMP) testing laboratories and UK analytical chemistry facilities.
From there, Lucideon will undertake extensive method development and validation for the chemical testing required for the vaccine to be released to the market.
Tony Kinsella, Chief Executive at Lucideon, said: "We are very proud to be working with Wockhardt to ensure that vaccines are available to fight the Covid-19 pandemic.
"This work is of national and international significance and needs to be carried out quickly and accurately.
"Effective regulatory compliance is essential to enable Wockhardt to get the vaccine doses to the market.
"We have implemented new working patterns and made extra resource available at our pharmaceutical centre of excellence in Stoke-on-Trent to meet that need, and to produce results promptly and safely.
"As a global organisation, we are committed to working with our partners to fight coronavirus."
Lucideon provides materials consultancy, supported by comprehensive analytical testing facilities and pilot plant and feasibility capabilities, to industries around the globe, including pharmaceutical, medical devices, consumer healthcare, nuclear, aerospace and construction. It has sites in the UK and the US and accredited laboratories in Asia.